Marta Peciña, MD PhD
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Marta Peciña, MD PhD sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Marta Peciña, MD PhD: 4 sponsored US clinical trials, 1 recruiting.
Marta Peciña, MD PhD sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 1 trials.
Upper-quartile sponsor footprint
Marta Peciña, MD PhD sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments
NCT06976840
Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses
NCT04276259
Study of Naltrexone-Induced Blockade of Antidepressant Effects
NCT04322526
Study of Neural Responses Induced by Antidepressant Effects
NCT02674529
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
Where Marta Peciña, MD PhD enrollment is open (later-stage tilt)
1 recruiting of 4 indexed (25% open); 3 completed (75%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Depression (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Marta Peciña, MD PhD: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Marta Peciña, MD PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Marta Peciña, MD PhD page
4 registered trials is a research-attention snapshot, not an endorsement of Marta Peciña, MD PhD or any single study.
- 1 of Marta Peciña, MD PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Marta Peciña, MD PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Marta Peciña, MD PhD pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.